Annalee Armstrong

2 days ago | biospace.com | Annalee Armstrong

After some additional thought and market developments, Galapagos is reversing course on a series of plans that involved spinning out a portion of the company and finding a new CEO over the next year. Paul Stoffels will still exit the company, just sooner than expected. And the Belgian biotech will explore the potential sale of a clutch of cell therapy assets, which Stoffels brought into the company’s fold through a series of acquisitions over the past three years.

3 days ago | biospace.com | Annalee Armstrong

President Donald Trump’s executive order on drug pricing contains little detail about how exactly it will be implemented but may still fall in the “better than feared” category for the biopharma industry, according to analysts. The splashy announcement from the White House left Wall Street wanting more details. BMO Capital Markets analysts suggested that the order was “more bark than bite,” with questionable legal roots. “The announcement represents more of a headline risk vs.

3 days ago | biospace.com | Annalee Armstrong

The White House has announced a sweeping drug pricing policy package that will touch all edges of the pharmaceutical industry. The executive order to be signed by President Donald Trump Monday morning will affect drug prices from Medicare to the private markets and could impact various industry operations, including how biopharma companies source their drugs and how they protect their intellectual property.

6 days ago | biospace.com | Annalee Armstrong

This deep dive was originally published Apr. 2, 2025 as a special edition of Biopharm Executive. Subscribe to Biopharm Executive to receive market insights, deals, business stories and deep dives into key policy issues impacting biopharma. Peter Marks, the venerable head of the FDA’s Center for Biologics Evaluation and Research, has been forced out.

6 days ago | biospace.com | Annalee Armstrong

The biopharma world has been waiting with bated breath to see what President Donald Trump will do with the Inflation Reduction Act. Next week, we may finally know, as Trump teased in the Oval Office on Monday that a major drug pricing initiative is coming next week. The IRA has been extremely maligned by the industry, particularly the “pill penalty,” referring to the IRA’s longer period of protection from price negotiations for biologics than for small molecules.